Abstract 15546: Statin Therapy Reduced Carotid Wall Temperature in Patients With Familial Hyperlipidemia Syndromes
Introduction: Adults with familial hyperlipidemia (FH) either heterozygous hypercholesterolemia (hFH) or combined hyperlipidemia (FCH), are characterized by premature atherosclerosis. Recent data support that statin therapy, the cornerstone for the treatment of FH, reduces systemic inflammation.
Hypothesis: Given that microwave radiometry (MWR) has been used for the evaluation of vascular inflammation via temperature measurements we investigated, in a randomized study, the impact of statin use on carotid wall inflammation, as assessed by microwave MWR.
Methods: Fifty-six patients with familial hyperlipidemia, free of statin therapy for at least 6 months and 50 age and sex matched healthy individuals were finally recruited. FH patients were randomized to either simvastatin 40 mg or simvastatin 40 mg plus ezetimibe 10mg. FH patients refusing statin therapy (n=10) constituted the control group for the assessment of statins effect. All the subjects underwent assessment of carotid thermal heterogeneity (temperature difference-Δτ) using MWR. Common carotid intima-media thickness (ccIMT) was also assessed. Examinations were performed at baseline in all the subjects and after 6 months in FH patients. Blood’s lipid profile was obtained in all FH patients.
Results: At baseline, FH patients exhibit higher Δτ measurements compared to healthy individuals (0.86±0.42°C vs 0.25±0.11°C, p<0.001). Similarly, they had increased ccIMT (0.14±0.13 vs 0.07±0.018 mm, p=0.001). After 6 months, low-density lipoprotein (LDL) levels were reduced in FH patients who received statin therapy but not in control group (240.11± 103.64 vs 111.89±44.73, p<0.001 and 284.33±117.98 vs 246.33±44.02 mg/dl). Furthermore, although Δτ measurements had been reduced after statin therapy (0.89±0.4 vs 0.54±0.24°C, p<0.001), they had not been significantly influenced in control group (0.53±0.14 vs 0.83±0.43°C, p=0.15).
Conclusions: Higher carotid wall inflammation and thickness were observed in FH patients compared to healthy subjects. Simvastatin therapy among the beneficial effect on LDL levels, reduced carotid wall inflammation in FH patients. The additive role of ezetimibe to simvastatin on carotid disease remains to be investigated in this specific population.
Author Disclosures: I. Koutagiar: None. K. Toutouzas: None. J. Skoumas: None. G. Benetos: None. C. Aggeli: None. A. Rigatou: None. S. Galanakos: None. E. Tsiamis: None. E. Siores: None. D. Tousoulis: None.
- © 2016 by American Heart Association, Inc.